BriaCell to Present Bria-OTS+(TM) Preclinical Data at SITC 2025 Annual Meeting

On October 3, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40 th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The details are listed below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance
Abstract Number: 353
Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
Date: Friday, Nov. 7, 2025

Following the presentation, a copy of the poster will be made available at View Source

(Press release, BriaCell Therapeutics, OCT 3, 2025, View Source [SID1234656934])

Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

On October 3, 2025 Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, reported the presentation of updated Phase 2 data from its ongoing study of imneskibart (AU-007) in patients with checkpoint inhibitor (CPI)-refractory melanoma and non-small cell lung cancer (NSCLC) (Press release, Aulos Bioscience, OCT 3, 2025, View Source [SID1234656422]). The data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40th Annual Meeting, being held virtually and in National Harbor, Maryland, from November 5-9, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Poster Title: Imneskibart, a human monoclonal antibody (mAb) that binds IL-2 and prevents CD25 binding, + low-dose subcutaneous IL-2: Phase 2 update on CPI-refractory melanoma and non-small cell lung cancer (NSCLC)
Abstract: 651
Date and Time: Friday, November 7, 2025, 10:00 a.m.-7:00 p.m. EST

The poster will be presented in the Prince George ABC Exhibit Halls at the Gaylord National Resort and Convention Center. An electronic version will also be available on the SITC (Free SITC Whitepaper) 2025 virtual meeting platform.

About Imneskibart
Imneskibart (AU-007) is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, imneskibart redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. Imneskibart also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

To learn more about the imneskibart Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: NCT05267626), www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com (Australia).

Ironfist Therapeutics Announces Preclinical Proof of Concept for Novel Nanomedicine Radiopharmaceutical, Tamrada™

On October 3, 2025 Ironfist Therapeutics ("Ironfist"), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor associated macrophages without a targeting ligand, reported the company will be presenting positive preclinical proof of concept results in anti-PD-1 resistant triple negative breast (TNB) cancer models using 177Lu-Tamrada at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) (Press release, Ironfist Therapeutics, OCT 3, 2025, View Source [SID1234656446]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These preclinical results coupled with our other 7 studies in a range of tumor types clearly demonstrate the therapeutic potential of targeting TAMs," said Jeffrey L Cleland, PhD, Chief Executive Officer of Ironfist Therapeutics.

TNB cancer is aggressive and unresponsive to anti-PD-1 antibody therapy in humans and preclinical models. Previous studies in the TNB cancer (4T1) mouse model presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI 2025) indicated a maximum 64Cu-Tamrada uptake of 41% ID/g in tumors. In this follow-up study, xenograft and orthotopic TNB cancer models were treated with the 177Lu-Tamrada at different radiation doses and regimens with and without anti-PD-1 antibody.

Key findings include:

Tamrada was tuned to optimize selectivity for TAMs and retention of 177Lu to maximize in vivo delivery to tumors
177Lu-Tamrada was retained in TAMs for over 10 days from a single administration (SPECT/CT)
177Lu-Tamrada alone caused tumor inhibition in both xenograft and orthotopic 4T1 mouse models
30 MBq 177Lu-Tamarada alone as a single or fractionated equivalent total dose (2x or 3x/week) caused significant (p < 0.05) tumor growth inhibition in orthotopic 4T1 tumor bearing mice compared to vehicle and anti-PD-1 treated mice.
At equivalent total radiation doses, fractionated doses were better tolerated and caused greater tumor accumulation than single doses.
"These preclinical results coupled with our other 7 studies in a range of tumor types clearly demonstrate the therapeutic potential of targeting TAMs," said Jeffrey L Cleland, PhD, Chief Executive Officer of Ironfist Therapeutics. "With this theragnostic approach, 64Cu/177Lu-Tamrada has the potential to precisely treat a wide range of tumors, kill tumor cells through bystander effects, and unlock the immune system. We look forward to sharing our compelling efficacy results in a PSMA negative mouse model at a subsequent meeting in 2026."

Unlike other radiopharmaceutical approaches, Tamrada is tumor agnostic because it is directly targeting TAMs. TAMs protect the tumor from the immune system, stimulate angiogenesis, and generate metastases. The hydroxyl dendrimer core of Tamrada was tuned specifically for selective uptake by TAMs without off target uptake in other macrophages. Once taken up by TAMs, Tamrada is not metabolized and is retained within the cells for up to one month providing a persistent source of radiation in the tumor with systemic clearance within 2-3 days.

Presentation Details:

Selective Killing of Tumor Associated Macrophages with a [177Lu]Lu-Nanomedicine Unlocks Checkpoint Inhibition

Presentation Number:

OP-025

Session Number:

204

Session Title:

M2M Track – TROP Session – Radiopharmaceutical Sciences + Translational
Molecular Imaging & Therapy Committee: New Targets in

Session Date:

Sunday, October 5, 2025

Session Presentation Time:

9:20:00 AM

Session Hall:

Room 114

About Tamrada

Tumors often enlist tumor-associated macrophages (TAMs) as protectors, shielding them from the immune system. Tamrada changes the story — reprogramming or removing these suppressive cells so the immune system can see the tumor clearly and strike with full force. Tamrada is designed from the novel nanomedicine technology of hydroxyl dendrimers invented at Johns Hopkins University. The nanomedicine component of Tamrada is comparable in size to an antibody fragment, does not leave the vasculature except in tumors, and has renal and biliary clearance without metabolism. 64Cu/177Lu-Tamrada enables precision dosing of cancer patients using a theragnostic approach. 177Lu-Tamrada provides an additional benefit of a bystander effect by killing adjacent tumor cells. The nanomedicine in Tamrada is amendable to modifications to create a pipeline of radiopharmaceuticals with different radioisotopes.

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

On October 3, 2025 Coherus Oncology, Inc. (NASDAQ: CHRS), reported an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) being held November 5-9, 2025, in National Harbor, Maryland (Press release, Coherus Oncology, OCT 3, 2025, View Source [SID1234656423]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract # 640: CHS-114, an anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors.

Date: Saturday, November 8, 2025
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
In addition, CHS-114 will be featured in the upcoming Targets for Cancer IO: A Deep Dive live webinar series:
Development of Anti-CCR8 Ab – Mechanisms and Clinical Results
Webinar 6 will address the novel therapeutic target C-C chemokine receptor 8 (CCR8), its role in regulatory T cell (Treg) activity and immunosuppression, and the latest advances and insights in developing monoclonal antibodies that target this chemokine receptor as a promising new strategy to treat a variety of cancers.

Date and Time: October 22, 2025, 12:00 – 2:00 pm Eastern Time
Moderators: Enrico Lugli, PhD, Humanitas Research Hospital and Rahul Roychoudhuri, MD, PhD
University of Cambridge
Faculty: Rosh Dias, MD, MRCP, Coherus Oncology; Varun Kapoor, PhD, Coherus Oncology; Jo Van Ginderachter, PhD, Vrije Universiteit Brussel
To learn more about the webinar series and register to attend, visit SITC (Free SITC Whitepaper)’s Targets for Cancer IO: A Deep Dive website: View Source

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

On October 3, 2025 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported it will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Transgene, OCT 3, 2025, View Source [SID1234656448]). SITC (Free SITC Whitepaper) will take place November 5 to 9, 2025, in National Harbor, Maryland, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster details

Title: "Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized Phase 1 trial for locally advanced resected HPV negative HNSCC".

Poster and abstract number: 502
Date: November 8, 2025
Author: C. Le Tourneau
The abstract will be available on the SITC (Free SITC Whitepaper) website on November 4, 2025, at 9 a.m. ET.

TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac technology and powered by NEC’s longstanding artificial intelligence (AI) expertise. TG4050 is being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166).

Transgene previously presented in a rapid oral presentation at the ASCO (Free ASCO Whitepaper) conference in June 2025, that all patients from Phase I who received TG4050 remained disease-free after a minimum of 2-year follow-up, comparing favorably to the observational arm which saw 3 out of 16 patients relapse during the same time period.

Transgene and NEC are continuing the joint development of TG4050 in this indication with a Phase II extension of the trial, which is currently enrolling patients.